Phase 3 - Evaluation of Veregen 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis
Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to show superiority of Veregen 10% ointment to Placebo measured by complete (100%) clearance of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).
Phase:
PHASE3
Details
Lead Sponsor:
Aresus Pharma GmbH
Treatments:
green tea extract polyphenone E Ointments Therapeutics